Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2017 02/17/2017 02/21/2017 02/22/2017 02/23/2017 Date
70.31(c) 69.85(c) 69.29(c) 68.83(c) 69.37(c) Last
10 965 471 11 186 926 11 190 406 10 073 355 7 529 059 Volume
+0.73% -0.65% -0.80% -0.66% +0.78% Change
More quotes
Financials ($)
Sales 2017 24 644 M
EBIT 2017 15 598 M
Net income 2017 10 931 M
Finance 2017 306 M
Yield 2017 3,09%
Sales 2018 23 035 M
EBIT 2018 14 047 M
Net income 2018 9 664 M
Finance 2018 1 791 M
Yield 2018 3,33%
P/E ratio 2017 8,89
P/E ratio 2018 9,40
EV / Sales2017 3,70x
EV / Sales2018 3,89x
Capitalization 91 392 M
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.Its primary areas of focus include primary areas of focus include human immunodeficiency virus, liver diseases such as chronic... 
More about the company
Surperformance© ratings of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES, INC.
05:39a GILEAD SCIENCES : Presents New Phase 2 Data on Bictegravir, an Investigational I..
02:11a GILEAD SCIENCES : Study Findings from Department of Immunology Provide New Insig..
02:10a GILEAD SCIENCES : Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences
02/23 GILEAD SCIENCES, INC. (NASDAQ : GILD) EPCLUSA Access To Be Provided In Ontario F..
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/22 GILEAD SCIENCES : Ontario Becomes First Province To List EPCLUSA™ On Publi..
02/21 SAREPTA THERAPEUTICS, INC. (NASDAQ : SRPT) Files An 8-K Entry into a Material De..
02/19 GILEAD SCIENCES : Price gouging of lifesaving drugs raises alarms, threatens bud..
02/16 GILEAD SCIENCES : to Present at the RBC Capital Markets 2017 Global Healthcare C..
02/16 GILEAD SCIENCES : New Antiretrovirals Data Have Been Reported by Researchers at ..
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on GILEAD SCIENCES, INC. 
2014A valuable trading opportunity
2014Continuation of the bullish trend
More Strategies
Latest Tweets
03:55aMaking (good) deals is hard to do, Gilead CEO says, but he's working on it
6
02/23AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink
3
02/23$GILD EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C  
02/23GlaxoSmithKline's Valuation Is Compelling
2
02/23REPORT: Carl Icahn can't make the $90B market cap Bristol-Myers a takeover ta..
3
More tweets
Qtime:330
News from SeekingAlpha
02/23 Can 20 Financial Ratios Measure A Company's Moat Just Like Morningstar? Updat..
02/23 GlaxoSmithKline's Valuation Is Compelling
02/23 SEEKING ALPHA INTERVIEWS : Bret Jensen On Promising Drugs And Acquisition Target..
02/23 Incyte Is Undervalued - Cramer's Lightning Round (2/22/17)
02/22 The S&P 500's 10 Cheapest Stocks By P/E - Here's Why GM Is The One To Buy
Advertisement
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 83,8 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-3.13%91 392
AMGEN, INC.18.06%128 150
CELGENE CORPORATION3.04%92 936
REGENERON PHARMACEUTIC..0.85%38 291
ACTELION LTD22.45%28 790
VERTEX PHARMACEUTICALS..16.45%21 264
More Results